Nobel laureate KaelinLab gave a special UTSW Internal Medicine grand rounds this AM during the #SeldinSymposium — his journey from Duke University School of Medicine to Johns Hopkins Medicine & Harvard Medical School Dana-Farber & discoveries for anemia, ischemia, & #kidneycancer along the way. UTSW Simmons Cancer Center

Natalie S. Callander, MD, on Multiple Myeloma: Management Updates ascopost.com/videos/2024-nc… #mmsm #MultipleMyeloma Natalie Callander UW Health | Carbone Cancer Center #hematology #guidelines #NCCN2024 National Comprehensive Cancer Network (NCCN)

Nobel laureate Dr. William Kaelin delivers the Seldin Symposium keynote address to a packed house! ⁦UT Southwestern Medical Center⁩ ⁦Thomas Wang, MD⁩ ⁦UTSW Internal Medicine Chiefs⁩ #SeldinSymposium2024

And excellent #MMsm editorial by Joshua Richter, MD, FACP!

When we need a bridge over troubled water (well played), use alkylators but don’t overuse them.

Plus an intriguing nod to GPRC5D bsAbs as bridging before BCMA CAR-T… Science at work!

nature.com/articles/s4140…

See also accompanying editorial on Bridging Therapy for CAR-T in myeloma. Joshua Richter, MD, FACP The Tisch Cancer Institute
#OpenAccess

nature.com/articles/s4140…

Real world data on bridging therapy for CAR-T. Report by U.S. Myeloma Immunotherapy Consortium Aimaz Afrough Yi Lin Surbhi Sidana, MD Gurbakhash Kaur Larry Anderson,MD,PhD,FACP Shonali Midha, M.D. Hamza Hashmi Krina Patel Douglas W. Sborov MD MS Omar Nadeem et al.

nature.com/articles/s4140…

ODAC unanimously votes in favor of using #MRD as an early endpoint for accelerated approval in #myeloma trials

This was a huge team effort for more than 8 years and with the generosity of unprecedented data sharing from many investigators around the world. Thank you all!
#mmsm

Great work i2TEAMM - specially leaders Nikhil C. Munshi, MD Brian Durie, M.D. and Jesus San Miguel. #MRD

International Myeloma Foundation Yelak Biru FDA Oncology

Huge step forward for #MMsm as with green light for MRD as ☝️ endpoint in trials - thanks C. Ola Landgren, M.D. Brian Durie, M.D. and many more for leadership here!

We always say as a field to sequence our best treatments first - now we’ll be able to bring them into the fold even earlier!

Great #MMsm work by Aimaz Afrough Larry Anderson,MD,PhD,FACP Yi Lin and many more!

Hopefully bridging will be a thing of the past in 5 years with rapid CAR manufacturing. Until then - personalize bridging intensity and don’t assume that forcing a PR with VD-PACE is helpful!

A great honor. Thanks again to ASTCT #CRTC for supporting our research in chronic #GVHD , and my Duke Hematologic Malignancies & Cellular Therapy mentors Mitch Horwitz and stefanie. #Tandem24

FDA Approves Bi-weekly Teclistamab Dosing for Relapsed/Refractory Multiple Myeloma onclive.com/view/fda-appro… via @onclive

Reduced dose of 1.5 mg/kg every 2 weeks in patients who achieve & maintain remission (CR) for at least 6 months

#mmsm International Myeloma Foundation Multiple Myeloma RF @HealthtreeMM

Awesome job by our awesome postdoc Aishwarya Sannareddy #Tandem24

Check out the presentation by our stellar IM resident Harsh Vardhan Upreti, missing Jimmy Lee #Tandem24

Check out our stellar AYA attending excellent job #Tandem24 ⁦Vivian Irizarry Gatell⁩

Murali Janakiram presenting RWE of outcomes of immune effector therapy post ide-cel relapse at #Tandem24
Great effort by #USMyelomaConsortium Surbhi Sidana, MD Gurbakhash Kaur Shebli Atrash Aimaz Afrough Krina Patel